Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C12H16F3N |
| Molecular Weight | 231.2573 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCNC(C)CC1=CC(=CC=C1)C(F)(F)F
InChI
InChIKey=DBGIVFWFUFKIQN-UHFFFAOYSA-N
InChI=1S/C12H16F3N/c1-3-16-9(2)7-10-5-4-6-11(8-10)12(13,14)15/h4-6,8-9,16H,3,7H2,1-2H3
| Molecular Formula | C12H16F3N |
| Molecular Weight | 231.2573 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
DescriptionSources: https://www.drugbank.ca/drugs/DB00574Curator's Comment: description was created based on several sources, including
https://www.drugs.com/international/fenfluramine.html | https://www.ncbi.nlm.nih.gov/pubmed/24790728 | https://clinicaltrials.gov/ct2/show/NCT02655198 | https://www.ncbi.nlm.nih.gov/pubmed/27264138 | https://www.ncbi.nlm.nih.gov/pubmed/22554283 | https://www.ncbi.nlm.nih.gov/pubmed/26600876
Sources: https://www.drugbank.ca/drugs/DB00574
Curator's Comment: description was created based on several sources, including
https://www.drugs.com/international/fenfluramine.html | https://www.ncbi.nlm.nih.gov/pubmed/24790728 | https://clinicaltrials.gov/ct2/show/NCT02655198 | https://www.ncbi.nlm.nih.gov/pubmed/27264138 | https://www.ncbi.nlm.nih.gov/pubmed/22554283 | https://www.ncbi.nlm.nih.gov/pubmed/26600876
Fenfluramine (former brand names Pondimin, Ponderax and Adifax), also known as 3-trifluoromethyl-N-ethylamphetamine, is an anorectic that is no longer marketed. In combination with phentermine, it was part of the anti-obesity medication Fen-phen. Fenfluramine was introduced on the U.S. market in 1973 and withdrawn in 1997. It is the racemic mixture of two enantiomers, dexfenfluramine, and levofenfluramine. The drug increases the level of serotonin, a neurotransmitter that regulates mood, appetite and other functions. Fenfluramine causes the release of serotonin by disrupting vesicular storage of the neurotransmitter and reversing serotonin transporter function. The drug was withdrawn from the U.S. market in 1997 after reports of heart valve disease and pulmonary hypertension, including a condition known as cardiac fibrosis. It was subsequently withdrawn from other markets around the world. In this small exploratory and retrospective study, remarkably good results were reported on the use of fenfluramine as an add-on medication for controlling seizures in patients with the Dravet syndrome. The side effects were rare and nonserious and did not result in termination of the treatment. It is possible that this drug may have anticonvulsive effects for other severe epilepsy syndromes, especially in those characterized by photosensitive or induced seizures.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0001820 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16237679 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Pondimin Approved UseUnknown |
|||
| Primary | Pondimin Approved UseUnknown |
|||
| Primary | Pondimin Approved UseUnknown |
|||
| Primary | Pondimin Approved UseUnknown |
|||
| Primary | Pondimin Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
68 ng/mL |
0.35 mg/kg 2 times / day steady-state, oral dose: 0.35 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: |
FENFLURAMINE plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1390 ng × h/mL |
0.35 mg/kg 2 times / day steady-state, oral dose: 0.35 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: |
FENFLURAMINE plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
20 h |
0.35 mg/kg 2 times / day steady-state, oral dose: 0.35 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: |
FENFLURAMINE plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
50% |
0.35 mg/kg 2 times / day steady-state, oral dose: 0.35 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: |
FENFLURAMINE plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
60 mg/day 1 times / day steady, oral Highest studied dose Dose: 60 mg/day, 1 times / day Route: oral Route: steady Dose: 60 mg/day, 1 times / day Sources: |
unhealthy, 11 years |
|
0.2 mg/kg/day 2 times / day steady, oral Studied dose Dose: 0.2 mg/kg/day, 2 times / day Route: oral Route: steady Dose: 0.2 mg/kg/day, 2 times / day Sources: |
unhealthy, 11.7 ± 4.4 years (range: 3‐17 years) Health Status: unhealthy Age Group: 11.7 ± 4.4 years (range: 3‐17 years) Sex: M+F Sources: |
Other AEs: Decreased appetite... |
0.7 mg/kg/day 1 times / day steady, oral Studied dose Dose: 0.7 mg/kg/day, 1 times / day Route: oral Route: steady Dose: 0.7 mg/kg/day, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sex: unknown Sources: |
Disc. AE: Somnolence... AEs leading to discontinuation/dose reduction: Somnolence (3.3%) Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Decreased appetite | 2 patients | 0.2 mg/kg/day 2 times / day steady, oral Studied dose Dose: 0.2 mg/kg/day, 2 times / day Route: oral Route: steady Dose: 0.2 mg/kg/day, 2 times / day Sources: |
unhealthy, 11.7 ± 4.4 years (range: 3‐17 years) Health Status: unhealthy Age Group: 11.7 ± 4.4 years (range: 3‐17 years) Sex: M+F Sources: |
| Somnolence | 3.3% Disc. AE |
0.7 mg/kg/day 1 times / day steady, oral Studied dose Dose: 0.7 mg/kg/day, 1 times / day Route: oral Route: steady Dose: 0.7 mg/kg/day, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sex: unknown Sources: |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no | ||||
| no | ||||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212102Orig1s000ClinPharmR.pdf#page=6 Page: 6.0 |
no | |||
| no | ||||
| no | ||||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212102Orig1s000ClinPharmR.pdf#page=6 Page: 6.0 |
no | |||
| no | ||||
| no | ||||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212102Orig1s000ClinPharmR.pdf#page=6 Page: 6.0 |
no | |||
| no | ||||
| no | ||||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212102Orig1s000ClinPharmR.pdf#page=6 Page: 6.0 |
no | |||
| no | ||||
| no | ||||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212102Orig1s000ClinPharmR.pdf#page=6 Page: 6.0 |
no | |||
| no | ||||
| no | ||||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212102Orig1s000ClinPharmR.pdf#page=6 Page: 6.0 |
no | |||
| no | ||||
| no | ||||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212102Orig1s000ClinPharmR.pdf#page=6 Page: 6.0 |
no | |||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| minor | ||||
| minor | unlikely (co-administration study) Comment: The effect of coadministration of CBD on fenfluramine and norfenfluramine PK was evaluated in Study 1604. The study demonstrated that co-administration of CBD with ZX008 increased fenfluramine AUC0-t by approximately 59% and the Cmax was not changed significantly. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212102Orig1s000ClinPharmR.pdf#page=6 Page: 6.0 |
|||
| minor | unlikely (co-administration study) Comment: The effect of coadministration of CBD on fenfluramine and norfenfluramine PK was evaluated in Study 1604. The study demonstrated that co-administration of CBD with ZX008 increased fenfluramine AUC0-t by approximately 59% and the Cmax was not changed significantly. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212102Orig1s000ClinPharmR.pdf#page=6 Page: 6.0 |
|||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| yes | ||||
| yes | unlikely (co-administration study) Comment: The effect of coadministration of CBD on fenfluramine and norfenfluramine PK was evaluated in Study 1604. The study demonstrated that co-administration of CBD with ZX008 increased fenfluramine AUC0-t by approximately 59% and the Cmax was not changed significantly. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212102Orig1s000ClinPharmR.pdf#page=6 Page: 6.0 |
|||
| yes | unlikely (co-administration study) Comment: The effect of coadministration of CBD on fenfluramine and norfenfluramine PK was evaluated in Study 1604. The study demonstrated that co-administration of CBD with ZX008 increased fenfluramine AUC0-t by approximately 59% and the Cmax was not changed significantly. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212102Orig1s000ClinPharmR.pdf#page=6 Page: 6.0 |
Tox targets
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212102Orig1s000OtherR.pdf#page=38 Page: 38.0 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Retest reliability of prolactin response to dl-fenfluramine challenge in adults. | 2002-02 |
|
| Inhibition of cocaine self-administration by fluoxetine or D-fenfluramine combined with phentermine. | 2002-01-29 |
|
| Is long-term heavy alcohol consumption toxic for brain serotonergic neurons? Relationship between years of excessive alcohol consumption and serotonergic neurotransmission. | 2002-01-01 |
|
| Pharmacological studies of the acute effects of (+)-3,4-methylenedioxymethamphetamine on locomotor activity: role of 5-HT(1B/1D) and 5-HT(2) receptors. | 2002-01 |
|
| Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: lessons for the future in pathogenesis. | 2002 |
|
| Aortic and mitral fenfluramine-phentermine valvulopathy in 64 patients treated with anorectic agents. | 2001-12 |
|
| LY393558, a 5-hydroxytryptamine reuptake inhibitor and 5-HT(1B/1D) receptor antagonist: effects on extracellular levels of 5-hydroxytryptamine in the guinea pig and rat. | 2001-11-30 |
|
| MDMA and fenfluramine alter the response of the circadian clock to a serotonin agonist in vitro. | 2001-11-30 |
|
| Fenfluramine and phentermine. | 2001-11-06 |
|
| Fluorometric determination of DL-fenfluramine, DL-norfenfluramine and phentermine in plasma by achiral and chiral high-performance liquid chromatography. | 2001-11-05 |
|
| Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine. | 2001-11-03 |
|
| Effects of endogenous neurotransmitters on the in vivo binding of dopamine and 5-HT radiotracers in mice. | 2001-11 |
|
| Monoamine oxidase inhibition is unlikely to be relevant to the risks associated with phentermine and fenfluramine: a comparison with their abilities to evoke monoamine release. | 2001-10 |
|
| Operation for anorexigen-associated valvular heart disease. | 2001-10 |
|
| High performance liquid chromatography with UV detection for the simultaneous determination of sympathomimetic amines using 4-(4,5-diphenyl-1H-imidazole-2-yl)benzoyl chloride as a label. | 2001-10 |
|
| Neuroendocrine effects of d-fenfluramine and bromocriptine following repeated smoked cocaine in humans. | 2001-09-01 |
|
| Acute effects of D-fenfluramine on simultaneous measures of aggressive escape and impulsive responses of adult males with and without a history of conduct disorder. | 2001-09 |
|
| Acute anorectic effect of single and combined drugs in mice using a non-deprivation protocol. | 2001-09 |
|
| Risk factors for pulmonary arterial hypertension. | 2001-09 |
|
| The relationship between health-related quality of life and weight loss. | 2001-09 |
|
| Prolactin response to dl-fenfluramine challenge before and after treatment with paroxetine. | 2001-09 |
|
| Relationship between central serotonergic neurotransmission and reduction in alcohol intake by citalopram. | 2001-08-01 |
|
| Neuroendocrine serotonergic and dopaminergic responsivity in male schizophrenic patients during treatment with neuroleptics and after switch to risperidone. | 2001-08 |
|
| Hypothalamo-pituitary-adrenal axis dysfunction in chronic fatigue syndrome, and the effects of low-dose hydrocortisone therapy. | 2001-08 |
|
| Effects of dietary sucrose on hippocampal serotonin release: a microdialysis study in the freely-moving rat. | 2001-08 |
|
| Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors. | 2001-08 |
|
| Fenfluramine-induced pulmonary vasoconstriction: role of serotonin receptors and potassium channels. | 2001-08 |
|
| Effect of 5-HT on binding of [(11)C] WAY 100635 to 5-HT(IA) receptors in rat brain, assessed using in vivo microdialysis nd PET after fenfluramine. | 2001-08 |
|
| Pharmacologic options for the treatment of obesity. | 2001-07-15 |
|
| Low risk of significant echocardiographic valvulopathy in patients treated with anorectic drugs. | 2001-07 |
|
| Lack of effect of HPA axis hyperactivity on hormonal responses to d-fenfluramine in major depressed patients: implications for pathogenesis of suicidal behaviour. | 2001-07 |
|
| Prolactin response to d-fenfluramine in postmenopausal women on and off ERT: comparison with young women. | 2001-07 |
|
| Too late, again? | 2001-06-23 |
|
| [Serotonin receptor changes in depression: evidences and limitations]. | 2001-06-20 |
|
| Echocardiographic examination of women previously treated with fenfluramine: long-term follow-up of a randomized, double-blind, placebo-controlled trial. | 2001-06-11 |
|
| Bitter pills, bad medicine. | 2001-06-04 |
|
| "Diet pills" and major depression in the Canadian population. | 2001-06 |
|
| 3,4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions. | 2001-06 |
|
| Transcranial magnetic stimulation and antidepressive drugs share similar cellular effects in rat hippocampus. | 2001-06 |
|
| Serotonin transporter promoter polymorphism is associated with attenuated prolactin response to fenfluramine. | 2001-05-08 |
|
| By the way, doctor...I used a diet pill--fenfluramine--a few years ago, but stopped as soon as I heard about it causing heart-valve problems. My doctor has been doing echocardiograms on me every six months. So far, everything looks good. How long do you think I need to keep on getting these checkups? | 2001-05 |
|
| Stress hormone dysregulation at rest and after serotonergic stimulation among alcohol-dependent men with extended abstinence and controls. | 2001-05 |
|
| Rapid clot formation and abnormal fibrin structure in a symptomatic patient taking fenfluramine--a case report. | 2001-05 |
|
| Decreased tryptophan availability but normal post-synaptic 5-HT2c receptor sensitivity in chronic fatigue syndrome. | 2001-05 |
|
| Effects of repeated systemic administration of d-Fenfluramine on serotonin and glutamate release in rat ventral hippocampus: comparison with methamphetamine using in vivo microdialysis. | 2001-04 |
|
| The quest for biological correlates of social phobia: an interim assessment. | 2001-04 |
|
| Understanding the neurobiology of suicidal behavior. | 2001 |
|
| Neuroendocrine responses to fenfluramine and its relationship to personality in alcoholism. | 2001 |
|
| High-speed liquid chromatography/tandem mass spectrometry using a monolithic column for high-throughput bioanalysis. | 2001 |
|
| Neurotransmitter and hormonal background of hostility in anorexia nervosa. | 2001 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22554283
0.12–0.90 mg/kg/day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19298257
Rat midbrain slices were used to make intracellular recordings from dopaminergic neurons of the substantia nigra and the ventral tegmental area. Gamma-aminobutyric acid (GABA)-mediated synaptic transmission was assessed from the inhibitory postsynaptic potentials (IPSPs) mediated by GABAA and GABAB receptors. Intracellular recordings from midbrain SNpc and VTA dopaminergic neurons were performed at 33.0 +/- 0.5°C in a recording chamber submerged with aCSF flowing at a rate of 2.5–3 mL•min-1 and continuously oxygenated, on the stage of an upright (inverted) microscope (Axioscope FS, Zeiss, Gottingen, Germany), equipped for infrared video microscopy (Hamamatsu, Tokyo, Japan) in order to allow a direct visualization of the recorded cells. Neurons, selected for their morphology, were identified as dopaminergic by their electrophysiological properties such as the presence of a regular spontaneous firing activity (0.5–4 Hz), a large inward current (Ih) in response to hyperpolarizing voltages and a membrane hyperpolarization due to dopamine (10–30 mmol•L-1) application . The recording electrodes were filled with 2 mol•L-1 KCl and had a tip resistance of 30–80 MW. GABAB synaptic potentials were evoked using a bipolar tungsten stimulating electrode with a tip separation of 300–700 mkm. Representative recordings showing the effect of fenfluramine in reducing the GABAB-mediated IPSP. Such effects were evident at concentrations below 1 mmol•L-1. The amplitude of synaptic potentials was halved by fenfluramine at concentration around 10 mmol•L-1 and was completely blocked by CGP (1 mmol•L-1), a selective GABAB receptor antagonist. Fenfluramine and sibutramine induce a concentration-dependent reduction of the GABAB-mediated inhibitory postsynaptic potentials (IPSPs).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:48:46 GMT 2025
by
admin
on
Mon Mar 31 17:48:46 GMT 2025
|
| Record UNII |
2DS058H2CF
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 216.24
Created by
admin on Mon Mar 31 17:48:46 GMT 2025 , Edited by admin on Mon Mar 31 17:48:46 GMT 2025
|
||
|
FDA ORPHAN DRUG |
584217
Created by
admin on Mon Mar 31 17:48:46 GMT 2025 , Edited by admin on Mon Mar 31 17:48:46 GMT 2025
|
||
|
NCI_THESAURUS |
C29728
Created by
admin on Mon Mar 31 17:48:46 GMT 2025 , Edited by admin on Mon Mar 31 17:48:46 GMT 2025
|
||
|
WHO-VATC |
QA08AA02
Created by
admin on Mon Mar 31 17:48:46 GMT 2025 , Edited by admin on Mon Mar 31 17:48:46 GMT 2025
|
||
|
WHO-ATC |
A08AA02
Created by
admin on Mon Mar 31 17:48:46 GMT 2025 , Edited by admin on Mon Mar 31 17:48:46 GMT 2025
|
||
|
DEA NO. |
1670
Created by
admin on Mon Mar 31 17:48:46 GMT 2025 , Edited by admin on Mon Mar 31 17:48:46 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
3337
Created by
admin on Mon Mar 31 17:48:46 GMT 2025 , Edited by admin on Mon Mar 31 17:48:46 GMT 2025
|
PRIMARY | |||
|
D005277
Created by
admin on Mon Mar 31 17:48:46 GMT 2025 , Edited by admin on Mon Mar 31 17:48:46 GMT 2025
|
PRIMARY | |||
|
4328
Created by
admin on Mon Mar 31 17:48:46 GMT 2025 , Edited by admin on Mon Mar 31 17:48:46 GMT 2025
|
PRIMARY | RxNorm | ||
|
100000081293
Created by
admin on Mon Mar 31 17:48:46 GMT 2025 , Edited by admin on Mon Mar 31 17:48:46 GMT 2025
|
PRIMARY | |||
|
5220-89-3
Created by
admin on Mon Mar 31 17:48:46 GMT 2025 , Edited by admin on Mon Mar 31 17:48:46 GMT 2025
|
SUPERSEDED | |||
|
1150
Created by
admin on Mon Mar 31 17:48:46 GMT 2025 , Edited by admin on Mon Mar 31 17:48:46 GMT 2025
|
PRIMARY | |||
|
3080
Created by
admin on Mon Mar 31 17:48:46 GMT 2025 , Edited by admin on Mon Mar 31 17:48:46 GMT 2025
|
PRIMARY | |||
|
C81418
Created by
admin on Mon Mar 31 17:48:46 GMT 2025 , Edited by admin on Mon Mar 31 17:48:46 GMT 2025
|
PRIMARY | |||
|
FENFLURAMINE
Created by
admin on Mon Mar 31 17:48:46 GMT 2025 , Edited by admin on Mon Mar 31 17:48:46 GMT 2025
|
PRIMARY | |||
|
2DS058H2CF
Created by
admin on Mon Mar 31 17:48:46 GMT 2025 , Edited by admin on Mon Mar 31 17:48:46 GMT 2025
|
PRIMARY | |||
|
1596
Created by
admin on Mon Mar 31 17:48:46 GMT 2025 , Edited by admin on Mon Mar 31 17:48:46 GMT 2025
|
PRIMARY | |||
|
5000
Created by
admin on Mon Mar 31 17:48:46 GMT 2025 , Edited by admin on Mon Mar 31 17:48:46 GMT 2025
|
PRIMARY | |||
|
2DS058H2CF
Created by
admin on Mon Mar 31 17:48:46 GMT 2025 , Edited by admin on Mon Mar 31 17:48:46 GMT 2025
|
PRIMARY | |||
|
CHEMBL87493
Created by
admin on Mon Mar 31 17:48:46 GMT 2025 , Edited by admin on Mon Mar 31 17:48:46 GMT 2025
|
PRIMARY | |||
|
4613
Created by
admin on Mon Mar 31 17:48:46 GMT 2025 , Edited by admin on Mon Mar 31 17:48:46 GMT 2025
|
PRIMARY | |||
|
458-24-2
Created by
admin on Mon Mar 31 17:48:46 GMT 2025 , Edited by admin on Mon Mar 31 17:48:46 GMT 2025
|
PRIMARY | |||
|
207-276-3
Created by
admin on Mon Mar 31 17:48:46 GMT 2025 , Edited by admin on Mon Mar 31 17:48:46 GMT 2025
|
PRIMARY | |||
|
SUB07561MIG
Created by
admin on Mon Mar 31 17:48:46 GMT 2025 , Edited by admin on Mon Mar 31 17:48:46 GMT 2025
|
PRIMARY | |||
|
DB00574
Created by
admin on Mon Mar 31 17:48:46 GMT 2025 , Edited by admin on Mon Mar 31 17:48:46 GMT 2025
|
PRIMARY | |||
|
25990-46-9
Created by
admin on Mon Mar 31 17:48:46 GMT 2025 , Edited by admin on Mon Mar 31 17:48:46 GMT 2025
|
SUPERSEDED | |||
|
m5274
Created by
admin on Mon Mar 31 17:48:46 GMT 2025 , Edited by admin on Mon Mar 31 17:48:46 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID4023044
Created by
admin on Mon Mar 31 17:48:46 GMT 2025 , Edited by admin on Mon Mar 31 17:48:46 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TRANSPORTER -> INHIBITOR | |||
|
|
OFF-TARGET->AGONIST |
5-HT2B receptors, which were subsequently identified as the target for cardiac valvulopathy and pulmonary hypertension. Release of serotonin leads to 5-HT2B signaling.
|
||
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
|
TARGET -> AGONIST |
STIMULATES THE RELEASE OF SEROTONIN RESULTS IN APPETITE SUPPRESSION; LEAD TO 6-16 FOLD INCREASE IN SEROTONIN IN THE HYPOTHALMUS
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
TRANSPORTER -> SUBSTRATE |
STIMULATES SEROTONIN RELEASE.
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE -> PARENT |
Percent of dose excreted in urine as metabolite.
AMOUNT EXCRETED
URINE
|
||
|
|
METABOLITE TOXIC -> PARENT |
Responsible for
MAJOR
|
||
|
METABOLITE -> PARENT |
Metabolite to parent drug ratio in non-uraemic human plasma.
A positive correlation exists between plasma norfenfluramine levels and weight loss in man.
METABOLITE TO PARENT DRUG RATIO
PLASMA; URINE
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|